Shares of Dice Therapeutics Inc. DICE, +67.34% soared 88.8% in premarket trading on Tuesday after the company shared promising Phase 1 data for its experimental psoriasis treatment. Dice said the investigational oral therapy was well-tolerated and showed a mean percentage reduction in the Psoriasis Area and Severity Index. “We look forward to advancing DC-806 into a Phase 2b clinical trial to optimize dosing and further explore peak efficacy with a longer duration of treatment,” Tim Lu, Dice’s chief medical officer, said in a news release. The company plans to submit a new drug application to the Food and Drug Administration in the first half of next year. Dice’s stock is down 2.6% this year, while the S&P 500 SPX, -0.09% has declined 21.4%.
